| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SLC25A20 |
| Uniprot No | O43772 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-301aa |
| 氨基酸序列 | MADQPKPISPLKNLLAGGFGGVCLVFVGHPLDTVKVRLQTQPPSLPGQPPMYSGTFDCFRKTLFREGITGLYRGMAAPIIGVTPMFAVCFFGFGLGKKLQQKHPEDVLSYPQLFAAGMLSGVFTTGIMTPGERIKCLLQIQASSGESKYTGTLDCAKKLYQEFGIRGIYKGTVLTLMRDVPASGMYFMTYEWLKNIFTPEGKRVSELSAPRILVAGGIAGIFNWAVAIPPDVLKSRFQTAPPGKYPNGFRDVLRELIRDEGVTSLYKGFNAVMIRAFPANAACFLGFEVAMKFLNWATPNL |
| 预测分子量 | 59.9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SLC25A20重组蛋白的3篇参考文献及其摘要概括：
1. **《Functional characterization of recombinant human mitochondrial carnitine/acylcarnitine carrier (SLC25A20) in yeast》**
- **作者**：Palmieri, F. et al.
- **摘要**：通过酵母表达系统重组表达人源SLC25A20蛋白，证实其作为肉碱/酰基肉碱转运体的功能，并利用放射性标记底物检测其转运活性，为脂肪酸氧化代谢研究提供模型。
2. **《Mutations in SLC25A20 disrupt mitochondrial carnitine transport and cause early-onset metabolic crises》**
- **作者**：Indiveri, C. et al.
- **摘要**：研究SLC25A20基因突变对重组蛋白功能的影响，发现突变导致线粒体肉碱转运缺陷，与新生儿代谢紊乱(如低酮性低血糖和心肌病)直接相关。
3. **《Structural insights into the substrate recognition mechanism of SLC25A20 transporter》**
- **作者**：Stroud, D.A. et al.
- **摘要**：通过冷冻电镜解析SLC25A20重组蛋白的三维结构，揭示其底物结合口袋的关键氨基酸残基，阐明酰基肉酸选择性转运的分子机制。
注：以上为模拟文献摘要，实际文献需通过学术数据库(如PubMed)检索确认。
SLC25A20. also known as carnitine-acylcarnitine translocase (CACT), is a mitochondrial membrane protein critical for fatty acid β-oxidation. It belongs to the solute carrier family 25 (SLC25), a group of nuclear-encoded transporters that shuttle metabolites, nucleotides, and cofactors across the mitochondrial inner membrane. SLC25A20 specifically facilitates the exchange of acylcarnitines (generated in the cytosol) with free carnitine across the membrane, enabling the transport of long-chain fatty acids into the mitochondrial matrix for energy production via β-oxidation. This process is essential for maintaining cellular energy homeostasis, particularly in tissues with high metabolic demands like skeletal muscle, heart, and liver.
Mutations in the *SLC25A20* gene cause carnitine-acylcarnitine translocase deficiency (CACTD), a rare autosomal recessive disorder characterized by impaired fatty acid oxidation, leading to life-threatening metabolic crises, cardiomyopathy, and hepatic dysfunction. Studying SLC25A20's structure-function relationship and pathological mechanisms requires high-purity recombinant protein. Recombinant SLC25A20 is typically produced using heterologous expression systems (e.g., *E. coli*, yeast, or mammalian cells*) engineered to express the protein with affinity tags (e.g., His-tag) for purification via chromatography. Structural studies suggest it forms a homodimer with six transmembrane helices, adopting a conserved "triple-domain" fold common to mitochondrial carriers.
Research applications include *in vitro* transport assays, inhibitor screening, and antibody production. Recombinant SLC25A20 also aids in developing therapeutic strategies, such as enzyme replacement or gene therapy for CACTD. Challenges remain in maintaining its native conformation post-purification, as mitochondrial carriers are prone to aggregation. Advances in membrane protein expression systems and cryo-EM are expected to deepen insights into its mechanistic role and disease-related dysregulation.
×
